Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024367462> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W3024367462 endingPage "S23" @default.
- W3024367462 startingPage "S23" @default.
- W3024367462 abstract "In this international, single-arm, open-label, multicenter, phase 2 trial (NCT02155647), treatment-naive patients with metastatic Merkel cell carcinoma (MCC) received avelumab 10 mg/kg treatment every 2 weeks with a follow-up of ≥15 months. In this preplanned sub-analysis, a patient-relevant endpoint of health-related quality of life (HRQOL) deterioration-free survival (QFS) was evaluated in relation to the typically used clinical endpoint, progression-free survival (PFS). HRQOL outcomes were assessed using the disease-specific Functional Assessment of Cancer Therapy - Melanoma (FACT-M) and the generic EQ-5D questionnaires. QFS was defined as a definite deterioration in terms of HRQOL, with “deterioration” defined as a patient reaching or exceeding a predefined minimal important difference threshold of deterioration at least once during the study and no further improvement thereafter. QFS was reported as (1) median QFS time in months and (2) QFS rates (ie, percentage of patients who had deteriorated at 6 and 12 months). Median QFS and QFS rates were qualitatively compared with median PFS and PFS rates, respectively. In 116 patients enrolled in this study, the HRQOL questionnaire compliance rate was over 75% across the study period. Median QFS was longer across all HRQOL scores (range of medians, 4.5-20.9 months) when compared with median PFS (4.1 months; 95% CI: 1.4-6.1 months). Furthermore, QFS rates were consistently higher/better (6-month data: range, 49%-72%; 12-month data: range, 40%-58%) compared with PFS rates of 41% and 31% at 6 and 12 months, respectively. These findings show unique, long-term HRQOL data for a rare condition, metastatic MCC. The substantially longer median QFS and substantially higher QFS rates compared with PFS estimates suggest patient-relevant, positive outcomes in the context of an aggressive cancer like MCC, with several patients reporting stable or improved HRQOL with avelumab treatment across time points." @default.
- W3024367462 created "2020-05-21" @default.
- W3024367462 creator A5002363544 @default.
- W3024367462 creator A5006448524 @default.
- W3024367462 creator A5018797846 @default.
- W3024367462 creator A5020435379 @default.
- W3024367462 creator A5025478490 @default.
- W3024367462 creator A5034066580 @default.
- W3024367462 creator A5036875036 @default.
- W3024367462 creator A5038218507 @default.
- W3024367462 creator A5040559926 @default.
- W3024367462 creator A5044289705 @default.
- W3024367462 creator A5061072132 @default.
- W3024367462 creator A5067776208 @default.
- W3024367462 creator A5077421764 @default.
- W3024367462 creator A5084003324 @default.
- W3024367462 creator A5084768366 @default.
- W3024367462 creator A5087492988 @default.
- W3024367462 creator A5087671839 @default.
- W3024367462 creator A5089731384 @default.
- W3024367462 creator A5091542924 @default.
- W3024367462 date "2020-05-01" @default.
- W3024367462 modified "2023-10-17" @default.
- W3024367462 title "PCN8 COMPARING PATIENT-RELEVANT ENDPOINT WITH CLINICAL ENDPOINT IN A RARE DISEASE: THE CASE OF METASTATIC MERKEL CELL CARCINOMA TREATED WITH AVELUMAB" @default.
- W3024367462 doi "https://doi.org/10.1016/j.jval.2020.04.1515" @default.
- W3024367462 hasPublicationYear "2020" @default.
- W3024367462 type Work @default.
- W3024367462 sameAs 3024367462 @default.
- W3024367462 citedByCount "0" @default.
- W3024367462 crossrefType "journal-article" @default.
- W3024367462 hasAuthorship W3024367462A5002363544 @default.
- W3024367462 hasAuthorship W3024367462A5006448524 @default.
- W3024367462 hasAuthorship W3024367462A5018797846 @default.
- W3024367462 hasAuthorship W3024367462A5020435379 @default.
- W3024367462 hasAuthorship W3024367462A5025478490 @default.
- W3024367462 hasAuthorship W3024367462A5034066580 @default.
- W3024367462 hasAuthorship W3024367462A5036875036 @default.
- W3024367462 hasAuthorship W3024367462A5038218507 @default.
- W3024367462 hasAuthorship W3024367462A5040559926 @default.
- W3024367462 hasAuthorship W3024367462A5044289705 @default.
- W3024367462 hasAuthorship W3024367462A5061072132 @default.
- W3024367462 hasAuthorship W3024367462A5067776208 @default.
- W3024367462 hasAuthorship W3024367462A5077421764 @default.
- W3024367462 hasAuthorship W3024367462A5084003324 @default.
- W3024367462 hasAuthorship W3024367462A5084768366 @default.
- W3024367462 hasAuthorship W3024367462A5087492988 @default.
- W3024367462 hasAuthorship W3024367462A5087671839 @default.
- W3024367462 hasAuthorship W3024367462A5089731384 @default.
- W3024367462 hasAuthorship W3024367462A5091542924 @default.
- W3024367462 hasBestOaLocation W30243674621 @default.
- W3024367462 hasConcept C121608353 @default.
- W3024367462 hasConcept C126322002 @default.
- W3024367462 hasConcept C141071460 @default.
- W3024367462 hasConcept C159110408 @default.
- W3024367462 hasConcept C203092338 @default.
- W3024367462 hasConcept C2777381376 @default.
- W3024367462 hasConcept C2777546739 @default.
- W3024367462 hasConcept C2777701055 @default.
- W3024367462 hasConcept C2778342957 @default.
- W3024367462 hasConcept C2779951463 @default.
- W3024367462 hasConcept C2780030458 @default.
- W3024367462 hasConcept C2780739268 @default.
- W3024367462 hasConcept C3019894029 @default.
- W3024367462 hasConcept C535046627 @default.
- W3024367462 hasConcept C71924100 @default.
- W3024367462 hasConceptScore W3024367462C121608353 @default.
- W3024367462 hasConceptScore W3024367462C126322002 @default.
- W3024367462 hasConceptScore W3024367462C141071460 @default.
- W3024367462 hasConceptScore W3024367462C159110408 @default.
- W3024367462 hasConceptScore W3024367462C203092338 @default.
- W3024367462 hasConceptScore W3024367462C2777381376 @default.
- W3024367462 hasConceptScore W3024367462C2777546739 @default.
- W3024367462 hasConceptScore W3024367462C2777701055 @default.
- W3024367462 hasConceptScore W3024367462C2778342957 @default.
- W3024367462 hasConceptScore W3024367462C2779951463 @default.
- W3024367462 hasConceptScore W3024367462C2780030458 @default.
- W3024367462 hasConceptScore W3024367462C2780739268 @default.
- W3024367462 hasConceptScore W3024367462C3019894029 @default.
- W3024367462 hasConceptScore W3024367462C535046627 @default.
- W3024367462 hasConceptScore W3024367462C71924100 @default.
- W3024367462 hasLocation W30243674621 @default.
- W3024367462 hasOpenAccess W3024367462 @default.
- W3024367462 hasPrimaryLocation W30243674621 @default.
- W3024367462 hasRelatedWork W2028889234 @default.
- W3024367462 hasRelatedWork W2064505821 @default.
- W3024367462 hasRelatedWork W2324321281 @default.
- W3024367462 hasRelatedWork W2740937461 @default.
- W3024367462 hasRelatedWork W2783234388 @default.
- W3024367462 hasRelatedWork W2899353411 @default.
- W3024367462 hasRelatedWork W2998951754 @default.
- W3024367462 hasRelatedWork W3024367462 @default.
- W3024367462 hasRelatedWork W4306253774 @default.
- W3024367462 hasRelatedWork W4308395740 @default.
- W3024367462 hasVolume "23" @default.
- W3024367462 isParatext "false" @default.
- W3024367462 isRetracted "false" @default.
- W3024367462 magId "3024367462" @default.
- W3024367462 workType "article" @default.